

# **Exhibit A**

IN THE UNITED STATES DISTRICT COURT  
FOR THE NORTHERN DISTRICT OF TEXAS  
DALLAS DIVISION


SOMAXON PHARMACEUTICALS, INC.	)	
AND PROCOM ONE, INC.,	)	
	)	
Plaintiffs,	)	
	)	
v.	)	
	)	
ACTAVIS ELIZABETH LLC,	)	
ACTAVIS, INC., MYLAN INC.,	)	
MYLAN PHARMACEUTICALS INC.,	)	
PAR PHARMACEUTICAL, INC., <i>et al.</i> ,	)	
	)	
Defendants.	)	Civil Action No. 3:22-MC-0044-C

**ORDER**

The Court, having considered Defendants and Counterclaim-Plaintiffs Mylan Pharmaceuticals Inc. and Mylan Inc.'s Motion to Quash, filed June 15, 2022, is of the opinion that the same should be **GRANTED IN PART** solely to the extent that said Motion be transferred. Specifically, the Court declines to issue a merits ruling as to Defendants' Motion as the transferee court currently has a scheduling order in place which contains a deadline for the close of fact discovery. Accordingly, the Court **ORDERS** that Defendants' Motion to Quash be **TRANSFERRED** to the United States District Court for the District of Delaware as this proceeding presents exceptional circumstances.<sup>1</sup> *See* Fed. R. Civ. P. 45(f).

SO ORDERED.

Dated June 21, 2022.

  
\_\_\_\_\_  
SAM R. CUMMINGS  
SENIOR UNITED STATES DISTRICT JUDGE

---

<sup>1</sup>*See Somaxon Pharmaceuticals Inc. et al. v. Actavis Elizabeth LLC et al.*, No. 1:10-CV-1100 (D. Del.).